A randomized, multicenter, international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer (CRPC)

被引：0
|
作者：
Pili, R.
Haggman, M.
Stadler, W. M.
Gingrich, J. R.
Assikis, V. J.
Bjork, A.
Forsberg, G.
Carducci, M. A.
Armstrong, A. J.
机构：
[1] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Pittsburgh, Pittsburgh, PA USA
[5] Peachtree Hematol Oncol, Atlanta, GA USA
[6] Act Biotech, Lund, Sweden
[7] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[8] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4510
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Long term safety and efficacy in a randomized multicenter international phase II study of tasquinimod in chemotherapy naive patients with metastatic castrate-resistant prostate cancer
    Armstrong, A. J.
    Gingrich, J. R.
    Haggman, M.
    Stadler, W. M.
    Damber, J. E.
    Belkoff, L.
    Clark, R.
    Brosman, S.
    Nordle, O.
    Forsberg, G.
    Carducci, M. A.
    Pili, R.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E126 - U515
  • [2] Phase II study of tasquinimod in chemotherapy-naive patients with metastatic castrate-resistant prostate cancer (CRPC): Safety and efficacy analysis including subgroups
    Armstrong, A. J.
    Haggman, M.
    Stadler, W. M.
    Gingrich, J. R.
    Assikis, V. J.
    Nordle, O.
    Forsberg, G.
    Carducci, M. A.
    Pill, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [3] A phase II randomized, open label study of sipuleucel-T versus sipuleucel-T and tasquinimod in patients with metastatic castrate-resistant prostate cancer (CRPC)
    Pill, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Randomized phase II trial of patupilone plus prednisone versus docetaxel plus prednisone in patients with chemotherapy-naive, metastatic, castrate-resistant prostate cancer(CRPC)
    De Souza, P. L.
    Mellado, B.
    Pfister, C.
    Rosenthal, M.
    Castellano, D. E.
    Weber, D.
    Ferrara, S.
    Shaik, N.
    Tan, E.
    Patterson, S. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy-Naive Metastatic Castrate-Resistant Prostate Cancer
    Heath, Elisabeth
    Heilbrun, Lance
    Mannuel, Heather
    Liu, Glenn
    Lara, Primo
    Monk, J. Paul
    Flaig, Thomas
    Zurita, Amado
    Mack, Philip
    Vaishampayan, Ulka
    Stella, Philip
    Smith, Daryn
    Bolton, Susan
    Hussain, Arif
    Al-Janadi, Anas
    Silbiger, Daniel
    Usman, Muhammad
    Ivy, S. Percy
    ONCOLOGIST, 2019, 24 (09): : 1149 - +
  • [6] A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive Castrate Resistant Prostate Cancer (CRPC)
    Beardsley, E. K.
    Hotte, S. J.
    Ellard, S.
    Winquist, E.
    North, S.
    Chi, K. N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 410 - 410
  • [7] Phase II Randomized, Double-Blind, Placebo-Controlled Study of Tasquinimod in Men With Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
    Pili, Roberto
    Haggman, Michael
    Stadler, Walter M.
    Gingrich, Jeffrey R.
    Assikis, Vasileios J.
    Bjork, Anders
    Nordle, Orjan
    Forsberg, Goran
    Carducci, Michael A.
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (30) : 4022 - 4028
  • [8] Phase II trial of bevacizumab monotherapy in nonmetastatic castrate-resistant prostate cancer (CRPC)
    Ogita, S.
    Tejwani, S.
    Heilbrun, L. K.
    Fontana, J. A.
    Heath, E. I.
    Freeman, S.
    Smith, D. W.
    Baranowski, K.
    Vaishampayan, U. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [9] MITOXANTRONE AS SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH CASTRATE-RESISTANT PROSTATE CANCER (CRPC)
    Morales, R.
    Valverde, C.
    Suarez, C.
    Brana, I.
    Planas, J.
    Padros, O.
    Maldonado, X.
    Morote, J.
    Carles, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 301 - 301
  • [10] BUDGET IMPACT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (CRPC) TO GERMAN PAYERS
    Jensen, I. S.
    Wu, C.
    Cyr, P. L.
    White, R. E.
    VALUE IN HEALTH, 2013, 16 (07) : A398 - A398
12345